Literature DB >> 35271732

The Modified E-Cigarette Evaluation Questionnaire: Psychometric Evaluation of an Adapted Version of the Modified Cigarette Evaluation Questionnaire for Use With Adults Who Use Electronic Nicotine Delivery Systems.

Meghan E Morean1, Krysten W Bold1.   

Abstract

INTRODUCTION: The subjective experience of positive and negative effects likely contributes to e-cigarette use, and the Modified Cigarette Evaluation Questionnaire (MCEQ) previously has been adapted to assess the reinforcing and aversive effects of vaping. However, the psychometric properties of the MCEQ for use with e-cigarettes have not been established. AIMS AND METHODS: We examined the psychometric properties of the Modified E-cigarette Evaluation Questionnaire (MECEQ) within a sample of 857 adults who recently used e-cigarettes in a smoking cessation attempt (52.4% male; 40.84 [12.25] years old; 62.8% non-Hispanic white; 22.4% daily e-cigarette users). Analyses included confirmatory factor analysis of the original structure, exploratory/confirmatory factor analyses to identify the alternate latent structure(s), internal consistency, measurement invariance, between-group differences, and test-criterion relationships with vaping-related outcomes.
RESULTS: The original five-factor structure and a novel four-factor structure were supported. Each was scalar invariant across several participant subgroups (eg, current smoking status, daily vaping status). All multi-item subscales were internally consistent. Both versions detected several between-group differences. For example, current smokers reported stronger aversive effects than did exclusive e-cigarette users. Finally, adjusted relationships between both MECEQ versions and vaping-related outcomes provided evidence for concurrent validity.
CONCLUSIONS: The five-factor and four-factor versions of the MECEQ evidenced good-to-excellent internal consistency, scalar measurement invariance, and concurrent relationships with vaping-related outcomes. While both versions could be used to assess subjective vaping effects in adults with histories of cigarette smoking and vaping, additional research is needed to evaluate the applicability of these factor structures to other samples (eg, e-cigarette users with no smoking history, youth). IMPLICATIONS: Although the MCEQ has been adapted in previously published studies to assess the subjective reinforcing and aversive effects of vaping, the psychometric foundation necessary for doing so had not been established. We showed that the MECEQ can be scored using the original five-factor MCEQ format or using a newly identified four-factor structure. Both versions evidenced construct validity, internal consistency, measurement invariance (permitting between-group comparisons), and concurrent validity with vaping-related outcomes. Results strengthen the interpretability of previously published work using the five-factor MCEQ structure and provide an alternative scoring approach for vaping-specific subjective effects.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2022        PMID: 35271732      PMCID: PMC9356680          DOI: 10.1093/ntr/ntac062

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   5.825


  14 in total

Review 1.  Addiction motivation reformulated: an affective processing model of negative reinforcement.

Authors:  Timothy B Baker; Megan E Piper; Danielle E McCarthy; Matthew R Majeskie; Michael C Fiore
Journal:  Psychol Rev       Date:  2004-01       Impact factor: 8.934

2.  Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire.

Authors:  Joseph C Cappelleri; Andrew G Bushmakin; Christine L Baker; Elizabeth Merikle; Abayomi O Olufade; David G Gilbert
Journal:  Addict Behav       Date:  2006-07-27       Impact factor: 3.913

3.  Confirmatory factor analysis of the Minnesota Nicotine Withdrawal Scale.

Authors:  Benjamin A Toll; Stephanie S O'Malley; Sherry A McKee; Peter Salovey; Suchitra Krishnan-Sarin
Journal:  Psychol Addict Behav       Date:  2007-06

4.  Psychometric Evaluation of the E-cigarette Dependence Scale.

Authors:  Meghan E Morean; Suchitra Krishnan-Sarin; Steve Sussman; Jonathan Foulds; Howard Fishbein; Rachel Grana; Stephanie S O'Malley
Journal:  Nicotine Tob Res       Date:  2019-10-26       Impact factor: 4.244

5.  Comparative fit indexes in structural models.

Authors:  P M Bentler
Journal:  Psychol Bull       Date:  1990-03       Impact factor: 17.737

6.  A Naturalistic, Randomized Pilot Trial of E-Cigarettes: Uptake, Exposure, and Behavioral Effects.

Authors:  Matthew J Carpenter; Bryan W Heckman; Amy E Wahlquist; Theodore L Wagener; Maciej L Goniewicz; Kevin M Gray; Brett Froeliger; K Michael Cummings
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-10       Impact factor: 4.254

7.  Signs and symptoms of tobacco withdrawal.

Authors:  J R Hughes; D Hatsukami
Journal:  Arch Gen Psychiatry       Date:  1986-03

8.  E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices.

Authors:  Michael B Steinberg; Mia Hanos Zimmermann; Cristine D Delnevo; M Jane Lewis; Parth Shukla; Elliot J Coups; Jonathan Foulds
Journal:  J Gen Intern Med       Date:  2014-05-15       Impact factor: 5.128

9.  A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes.

Authors:  Pasquale Caponnetto; Jennifer DiPiazza; Jason Kim; Marilena Maglia; Riccardo Polosa
Journal:  Nicotine Tob Res       Date:  2021-03-16       Impact factor: 4.244

10.  Sensory experiences and cues among E-cigarette users.

Authors:  J DiPiazza; P Caponnetto; G Askin; P Christos; M Lyc Psych Maglia; R Gautam; S Roche; R Polosa
Journal:  Harm Reduct J       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.